Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Status:
Recruiting
Trial end date:
2026-09-29
Target enrollment:
Participant gender:
Summary
Esophageal cancer, which has a low 5-year overall survival rate for all stages (<20%) , is
increasing in incidence. Previous studies have shown that the Hedgehog (Hh) and AKT signaling
pathways are activated in a significant proportion of esophageal cancers. Itraconazole, a
widely used anti-fungal medication, has been shown to inhibit various pathways involved in
esophageal cancer tumorigenesis including Hh and AKT. In this phase II clinical trial, the
investigators aim to evaluate the effect of itraconazole as a neoadjuvant therapy following
standard of care chemoradiation in the treatment of locoregional esophageal and
gastroesophageal junction carcinomas.